SALT LAKE CITY, Nov. 29, 2023 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN), a leading health and wellness company with products designed to activate optimal health processes, today ...
The new product, known as Protandim® NAD Synergizer™, is the company’s first such addition to the flagship line since the launch of Protandim® Nrf1 Synergizer™ in 2016.* “Our Protandim® line of ...
LITTLE ROCK, Ark.--(BUSINESS WIRE)--Kuria Therapeutics, a pharmaceutical company developing novel ophthalmic and dermal therapeutics, is pleased to announce it has completed a pre-Investigational New ...
C4X Discovery Holdings plc has outlicensed its once daily oral NRF2 (Nuclear factor-erythroid factor 2-related factor 2) activator to Astrazeneca plc in a deal with a potential value of $402 million.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results